| Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells W Fiskus, S Sharma, B Shah, BP Portier, SGT Devaraj, K Liu, SP Iyer, ... Leukemia 28 (11), 2155, 2014 | 291 | 2014 |
| Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells W Fiskus, S Sharma, J Qi, JA Valenta, LJ Schaub, B Shah, K Peth, ... Molecular cancer therapeutics 13 (5), 1142-1154, 2014 | 203 | 2014 |
| Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells K Ha, W Fiskus, DS Choi, S Bhaskara, L Cerchietti, SGT Devaraj, B Shah, ... Oncotarget 5 (14), 5637, 2014 | 157 | 2014 |
| BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD W Fiskus, S Sharma, J Qi, B Shah, SGT Devaraj, C Leveque, BP Portier, ... Molecular cancer therapeutics 13 (10), 2315-2327, 2014 | 150 | 2014 |
| Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib B Sun, B Shah, W Fiskus, J Qi, K Rajapakshe, C Coarfa, L Li, ... Blood, The Journal of the American Society of Hematology 126 (13), 1565-1574, 2015 | 118 | 2015 |
| Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells W Fiskus, S Sharma, S Saha, B Shah, SGT Devaraj, B Sun, S Horrigan, ... Leukemia 29 (6), 1267-1278, 2015 | 115 | 2015 |
| Towards lean warehouse: transformation and assessment using RTD and ANP S Sharma, B Shah International Journal of Productivity and Performance Management 65 (4), 571-599, 2016 | 70 | 2016 |
| HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist SGT Devaraj, W Fiskus, B Shah, J Qi, B Sun, SP Iyer, S Sharma, ... Leukemia 30 (2), 504-508, 2016 | 40 | 2016 |
| Thinking cloud-enabled adept and agile supply chain for SMEs: a conceptual study S Sharma, B Shah International Journal of Business Information Systems 19 (3), 342-365, 2015 | 20 | 2015 |
| Erratum: Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells W Fiskus, S Sharma, B Shah, BP Portier, SGT Devaraj, K Liu, SP Iyer, ... Leukemia 31 (7), 1658-1658, 2017 | 19 | 2017 |
| Mechanistic role of HEXIM1 induction in BRD4-antagonist mediated growth inhibition, differentiation and in vivo lethal activity against human aml blast progenitor cells SGT Devaraj, W Fiskus, B Shah, S Sharma, J Qi, B Sun, S Saha, SP Iyer, ... Blood 124 (21), 3534, 2014 | 2 | 2014 |
| Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell … B Sun, W Fiskus, B Shah, J Qi, SGT Devaraj, SP Iyer, S Sharma, ... Blood 124 (21), 918, 2014 | 1 | 2014 |
| BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors M Rodriguez, W Fiskus, S Sharma, J Qi, LJ Schaub, B Shah, SGT Devaraj, ... Cancer Research 74 (19_Supplement), 1721-1721, 2014 | 1 | 2014 |
| HEXIM1 induction exerts a mechanistic role and is a biomarker of lethal activity of BRD4 antagonist against human AML cells SGT Devaraj, W Fiskus, S Sharma, J Qi, B Shah, LJ Schaub, M Rodriguez, ... Cancer Research 74 (19_Supplement), 3686-3686, 2014 | 1 | 2014 |
| BRD4 antagonist and histone deacetylase inhibitor: a novel synergistic combination against human acute myeloid leukemia (AML) Cells W Fiskus, S Sharma, J Qi, JA Valenta, LJ Schaub, B Shah, K Peth, ... Blood 122 (21), 485, 2013 | 1 | 2013 |
| Combined therapy with BRD4 antagonist and FLT3 inhibitor exerts synergistic activity against cultured and primary AML blast progenitors expressing FLT-ITD M Rodriguez, W Fiskus, S Sharma, J Qi, JA Valenta, LJ Schaub, B Shah, ... Blood 122 (21), 3821, 2013 | 1 | 2013 |
| Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells JA Valenta, W Fiskus, T Manshouri, S Sharma, J Qi, LJ Schaub, B Shah, ... Blood 122 (21), 2842, 2013 | 1 | 2013 |
| Erratum: Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib (Blood (2015) 126: 13 (1565-1574)) B Sun, B Shah, W Fiskus Blood 128 (13), 1778, 2016 | | 2016 |
| Molecular mechanism of synergy between BET-protein bromodomain antagonist (BA) and pTEFb kinase inhibitor against human AML blast progenitor cells SGT Devaraj, B Shah, W Fiskus, B Sun, S Saha, SR Pingali, SP Iyer, ... Cancer Research 75 (15_Supplement), 2623-2623, 2015 | | 2015 |
| BET-protein bromodomain antagonist-based combinations against ibrutinb-sensitive or resistant human Mantle Cell Lymphoma cells B Sun, B Shah, W Fiskus, J Qi, SGT Devaraj, SP Iyer, S Sharma, ... Cancer Research 75 (15_Supplement), 2612-2612, 2015 | | 2015 |
